Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
The new program includes upstream and downstream process development and large-scale GMP production.
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Amarex Clinical Research guides its client to phase II of FDA trials
Tislelizumab is now approved in nine indications in China
TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Subscribe To Our Newsletter & Stay Updated
